Personalized vascular medicine: Individualizing drug therapy

Vascular Medicine

Volumn 16, Issue 5, 2011, Pages 391-404

  DeGoma, Emil M ^a   Rivera, Giovanni ^b   Lilly, Scott M ^a   Usman, M Haris U ^a   Mohler III, Emile R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

anticoagulants; antihypertensive agents; aspirin; statins; vascular diseases; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN A5; ARYLDIALKYLPHOSPHATASE 1; CILOSTAZOL; CLOPIDOGREL; EZETIMIBE; RENIN; SIMVASTATIN; WARFARIN;

ANTIHYPERTENSIVE THERAPY; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; GENOMICS; GENOTYPE; HEALTH CARE; HUMAN; HYPERTENSION; HYPOCHOLESTEROLEMIA; MEDICAL CARE; METABOLOMICS; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHYSICIAN; PRIORITY JOURNAL; PROTEOMICS; REVIEW; THROMBOCYTE AGGREGATION; VASCULAR DISEASE;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; FIBRINOLYTIC AGENTS; GENOTYPING TECHNIQUES; HUMANS; HYPOLIPIDEMIC AGENTS; INDIVIDUALIZED MEDICINE; PLATELET AGGREGATION INHIBITORS;

EID: 80054755086     PISSN: 1358863X     EISSN: 14770377     Source Type: Journal    
DOI: 10.1177/1358863X11422251     Document Type: Review

References (116)

1. Diseases III. Cambridge: Loeb Classic Library ; 1988 :
2. Lesko LJ. Personalized medicine: elusive dream or imminent reality?. Clin Pharmacol Ther. 2007 ; 81: 807-816 (Pubitemid 46788303)
3. Sykiotis GP, Kalliolias GD, Papavassiliou AG. Pharmacogenetic principles in the Hippocratic writings. J Clin Pharmacol. 2005 ; 45: 1218-1220 (Pubitemid 41513043)
4. Schlendorf KH, Nasir K, Blumenthal RS. Limitations of the Framingham risk score are now much clearer. Prev Med. 2009 ; 48: 115-116
5. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010 ; 122: e584-636
6. Kathiresan S, Melander O, Anevski D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med. 2008 ; 358: 1240-1249 (Pubitemid 351439225)
7. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007 ; 297: 611-619
8. Aspinall MG, Hamermesh RG. Realizing the promise of personalized medicine. Harv Bus Rev. 2007 ; 85: 108 165-117
9. Piquette-Miller M, Grant DM. The art and science of personalized medicine. Clin Pharmacol Ther. 2007 ; 81: 311-315 (Pubitemid 46364497)
10. Lunshof JE, Pirmohamed M, Gurwitz D. Personalized medicine: decades away?. Pharmacogenomics. 2006 ; 7: 237-241
11. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010 ; 363: 301-304
12. Woodcock J. The prospects for 'personalized medicine' in drug development and drug therapy. Clin Pharmacol Ther. 2007 ; 81: 164-169 (Pubitemid 46174812)
13. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 ; 324: 71-86
14. Yusuf S, Mehta SR, Zhao F, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation. 2003 ; 107: 966-972 (Pubitemid 36258718)
15. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001 ; 358: 527-533 (Pubitemid 32772726)
16. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005 ; 366: 1607-1621
17. Mehta JL, Mohandas B. Aspirin resistance: fact or fiction? A point of view. World J Cardiol. 2010 ; 2: 280-288
18. Migliorini A, Valenti R, Marcucci R, et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation. 2009 ; 120: 2214-2221
19. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin 'resistance' and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008 ; 336: 195-198 (Pubitemid 351212675)
20. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006 ; 27: 2420-2425 (Pubitemid 44522148)
21. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007 ; 49: 1505-1516 (Pubitemid 46517957)
22. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006 ; 48: 1742-1750 (Pubitemid 44648629)
23. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 2008 ; 51: 1829-1843 (Pubitemid 351615246)
24. Nielsen HL, Kristensen SD, Thygesen SS, et al. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. Thromb Res. 2008 ; 123: 267-273
25. Neubauer H, Kaiser AF, Endres HG, et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance-The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011 ; 9: 3
26. Gladding P, Webster M, Zeng I, et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv. 2008 ; 1: 620-627
27. Lev EI, Solodky A, Harel N, et al. Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. J Am Coll Cardiol. 2010 ; 55: 114-121
28. Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol. 2010 ; 55: 1671-1678
29. Suh JW, Lee SP, Park KW, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol. 2011 ; 57: 280-289
30. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol. 2009 ; 53: 1101-1109
31. Price MJ, Berger PB, Teirstein PS, et al. GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011 ; 305: 1097-1105
32. HeartWire, 'TRIGGER-PCI Halted', http://www.theheart.org/article/1200057. do (2011, accessed April 2011).
33. Chin CT, Roe MT, Fox KA, et al. TRILOGY ACS Steering Committee. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the Targeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J. 2010 ; 160: 16-22
34. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009 ; 360: 363-375
35. Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 2008 ; 84: 236-242
36. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010 ; 376: 1312-1319
37. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008 ; 51: 1925-1934 (Pubitemid 351636443)
38. Harmsze AM, van Werkum JW, Ten Berg JM, et al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J. 2010 ; 31: 3046-3053
39. Varenhorst C, James S, Erlinge D, et al. Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J. 2009 ; 157: 562 e1-9
40. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006 ; 108: 2244-2247 (Pubitemid 44497506)
41. Gladding P, Webster M, Zeng I, et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv. 2008 ; 1: 612-619
42. Barker CM, Murray SS, Teirstein PS, Kandzari DE, Topol EJ, Price MJ. Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. JACC Cardiovasc Interv. 2010 ; 3: 1001-1007
43. Kim IS, Jeong YH, Park Y, et al. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. JACC Cardiovasc Interv. 2011 ; 4: 381-391
44. Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011 ; 17: 110-116
45. Turner ST, Schwartz GL, Boerwinkle E. Personalized medicine for high blood pressure. Hypertension. 2007 ; 50: 1-5 (Pubitemid 46985999)
46. Izzo JL, Sica DA, Black HR American Heart Association Hypertension Primer. 4 th edition.New York: Lippincott Williams & Wilkins, 2007. New York: Lippincott Williams & Wilkins ; 2007 :
47. Laragh JH, Baer L, Brunner HR, Buhler FR, Sealey JE, Vaughan ED. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med. 1972 ; 52: 633-652
48. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens. 2001 ; 14: 307-310
49. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens. 2001 ; 14: 491-503 (Pubitemid 32506721)
50. Turner ST, Schwartz GL, Chapman AB, et al. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens. 2010 ; 23: 1014-1022
51. Preston RA, Materson BJ, Reda DJ, et al. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. JAMA. 1998 ; 280: 1168-1172 (Pubitemid 28457807)
52. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Pressor responses to antihypertensive drug types. Am J Hypertens. 2010 ; 23: 1031-1037
53. Egan BM, Basile JN, Rehman SU, et al. Plasma renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009 ; 22: 792-801
54. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010 ; 376: 1903-1909
55. Arnett DK, Davis BR, Ford CE, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation. 2005 ; 111: 3374-3383 (Pubitemid 40923390)
56. Harrap SB, Tzourio C, Cambien F, et al. The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension. 2003 ; 42: 297-303 (Pubitemid 37093476)
57. Brugts JJ, Isaacs A, Boersma E, et al. Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. Eur Heart J. 2010 ; 31: 1854-1864
58. Brugts JJ, Boersma E, Simoons ML. Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit. Pharmacogenomics. 2010 ; 11: 1115-1126
59. Furberg CD. Renin-guided treatment of hypertension: time for action. Am J Hypertens. 2010 ; 23: 929-930
60. Brown MJ. Heterogeneity of blood pressure response to therapy. Am J Hypertens. 2010 ; 23: 926-928
61. A cooperative study. JAMA. 1977 ; 237: 255-261
62. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 ; 42: 1206-1252 (Pubitemid 37553153)
63. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009 ; 27: 2121-2158
64. Sehgal AR. Overlap between whites and blacks in response to antihypertensive drugs. Hypertension. 2004 ; 43: 566-572 (Pubitemid 38282429)
65. Mokwe E, Ohmit SE, Nasser SA, et al. Determinants of blood pressure response to quinapril in black and white hypertensive patients: the Quinapril Titration Interval Management Evaluation trial. Hypertension. 2004 ; 43: 1202-1207 (Pubitemid 38691741)
66. Fonseca V, Bakris GL, Bell DS, et al. Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabet Med. 2007 ; 24: 759-763 (Pubitemid 47012128)
67. Torp-Pedersen C, Metra M, Charlesworth A, et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007 ; 93: 968-973 (Pubitemid 47122050)
68. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003 ; 362: 7-13 (Pubitemid 36835815)
69. Remme WJ, Torp-Pedersen C, Cleland JG, et al. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol. 2007 ; 49: 963-971 (Pubitemid 46335773)
70. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009 ; 122: 290-300
71. Spence JD. Physiologic tailoring of therapy for resistant hypertension: 20 years' experience with stimulated renin profiling. Am J Hypertens. 1999 ; 12: 1077-1083
72. Ostchega Y, Yoon SS, Hughes J, Louis T. Hypertension awareness, treatment, and control-continued disparities in adults: United States, 2005-2006. NCHS Data Brief. 2008 ; Jan (3). 1-8
73. Lancet. 1994 ; 344: 1383-1389
74. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 ; 360: 7-22
75. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 ; 359: 2195-2207
76. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 ; 361: 1149-1158 (Pubitemid 36398384)
77. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 ; 333: 1301-1307
78. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006 ; 114: 2788-2797 (Pubitemid 46018281)
79. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther. 2005 ; 19: 403-414 (Pubitemid 43228152)
80. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007 ; 356: 1503-1516 (Pubitemid 46588415)
81. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009 ; 360: 2503-2515
82. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 ; 362: 1563-1574
83. Gupta A, Thompson PD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis. 2011 ; 215: 23-29
84. Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis. 2010 ; 210: 337-343
85. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 ; 15: 513-522 (Pubitemid 41017600)
86. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007 ; 82: 726-733 (Pubitemid 350114817)
87. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006 ; 16: 873-879 (Pubitemid 44772805)
88. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008 ; 359: 789-799
89. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009 ; 54: 1609-1616
90. Brunham LR, Lansberg PJ, Zhang L, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 2011 ;:
91. Voora D, Ginsburg GS. Pharmacogenetics of the response to statins. Curr Cardiovasc Risk Rep. 2009 ; 3: 434-440
92. Glueck CJ, Aregawi D, Agloria M, et al. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Clin Ther. 2006 ; 28: 933-942 (Pubitemid 44062693)
93. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992 ; 85: 37-45
94. Circulation. 2000 ; 102: 21-27
95. Tai ES, Ordovas JM. Clinical significance of apolipoprotein A5. Curr Opin Lipidol. 2008 ; 19: 349-354
96. Lai CQ, Arnett DK, Corella D, et al. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler Thromb Vasc Biol. 2007 ; 27: 1417-1425 (Pubitemid 46809433)
97. Hegele RA, Pollex RL. Apolipoprotein A-V genetic variation and plasma lipoprotein response to fibrates. Arterioscler Thromb Vasc Biol. 2007 ; 27: 1224-1227 (Pubitemid 46809408)
98. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010 ; 160: 785-794
99. Hegele RA, Guy J, Ban MR, Wang J. NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis. 2005 ; 4: 16
100. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008 ; 84: 326-331
101. Glurich I, Burmester JK, Caldwell MD. Understanding the pharmacogenetic approach to warfarin dosing. Heart Fail Rev. 2010 ; 15: 239-248
102. Flockhart DA, O'Kane D, Williams MS, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008 ; 10: 139-150 (Pubitemid 351271726)
103. Tan GM, Wu E, Lam YY, Yan BP. Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics. 2010 ; 11: 439-448
104. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 2007 ; 7: 99-111 (Pubitemid 46567142)
105. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther. 2008 ; 83: 460-470 (Pubitemid 351272635)
106. Yang L, Ge W, Yu F, Zhu H. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis. Thromb Res. 2010 ; 125: e159-166
107. Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol. 2010 ; 55: 2804-2812
108. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007 ; 116: 2563-2570 (Pubitemid 350179221)
109. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009 ; 150: 73-83
110. McWilliam A, Lutter R, Nardinelli C. Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin. Per Med. 2008 ; 5: 279-284 (Pubitemid 351819084)
111. Kim MJ, Huang SM, Meyer UA, Rahman A, Lesko LJ. A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J Clin Pharmacol. 2009 ; 49: 138-146
112. Wrigley BJ, Lip GY, Shantsila E. Novel oral anticoagulants: the potential relegation of vitamin K antagonists in clinical practice. Int J Clin Pract. 2010 ; 64: 835-838
113. Rosove MH, Grody WW. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. Ann Intern Med. 2009 ; 151: 270 W95-273
114. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 ; 133: 160S - 198S (Pubitemid 351892967)
115. French B, Joo J, Geller NL, et al. COAG (Clarification of Optimal Anticoagulation through Genetics) Investigators. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials. 2010 ; 11: 108
116. Do EJ, Lenzini P, Eby CS, et al. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J. 2011 ; 1: 1-8